T. Rowe Price Associates
RUBY

T. Rowe Price Associates’s Rubius Therapeutics, Inc RUBY Stock Holding History

T. Rowe Price Associates’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-70,400
Closed -$31K – 3019
2022
Q3 		$31K Hold
70,400
– – ﹤0.01% 2888
2022
Q2 		$60K Sell
70,400
-914,246
-93% -$1.53M ﹤0.01% 2838
2022
Q1 		$5.42M Buy
984,646
+54,467
+6% +$346K ﹤0.01% 1455
2021
Q4 		$9M Buy
+930,179
New +$12.9M ﹤0.01% 1418

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's RUBY Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2022, closing a stake of 70,400 shares — an estimated $31K sold.

T. Rowe Price Associates first reported a position in RUBY in Q4 2021 and held it in 4 quarters. The position peaked at $9M in Q4 2021. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

  • T. Rowe Price Associates reported no remaining Rubius Therapeutics, Inc position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 70,400 Rubius Therapeutics, Inc shares in Q4 2022, an estimated $31K.
  • T. Rowe Price Associates first reported a position in Rubius Therapeutics, Inc in Q4 2021 and held it in 4 quarters.
  • T. Rowe Price Associates's Rubius Therapeutics, Inc position peaked at $9M in Q4 2021.
  • 42 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.